16.81
+0.1(+0.60%)
Currency In USD
Address
99 Hayden Avenue
Lexington, MA 02421
United States of America
Phone
617 314 6297
Website
Sector
Healthcare
Industry
Biotechnology
Employees
160
First IPO Date
April 08, 2020
| Name | Title | Pay | Year Born |
| Dr. Jasbir S. Seehra Ph.D. | Chief Executive Officer & Chair of the Board | 1.13M | 1956 |
| Mr. Keith C. Regnante MBA | Chief Financial Officer | 636,108 | 1970 |
| Mr. Christopher Rovaldi M.Sc. | President & Chief Operating Officer | 784,900 | 1974 |
| Dr. Yung H. Chyung M.D. | Chief Medical Officer | 0 | 1976 |
| Ms. Esther Cho J.D. | Senior Vice President, General Counsel & Secretary | 0 | N/A |
| Ms. Robin Wagner | Senior Vice President of Human Resources | 0 | N/A |
| Mr. John Oram M.B.A. | Senior Vice President of Program & Portfolio Management | 0 | N/A |
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.